. 2017 Jan-Mar;13(1):84–89. doi: 10.4183/aeb.2017.84

Table 3.

Insulin resistance parameters at baseline and after 12 months of treatment, and comparisons within and between patient groups

	Months	Group-1 (finasteride)	Group-2 (metformin)	Group-3 (combination)
HOMA-IR	0.	2.6 ± 0.6	3.5 ± 3.5^a	2.3 ± 1.7
HOMA-IR	12.	1.2 ± 0.7*^b	1.4 ± 1.3*	1.6 ± 1.2*^b
AUC-Glucose	0.	13098 ± 2895^b	15018 ± 5023	15939 ± 5195^b
AUC-Glucose	12.	12124 ± 1568*	11961 ± 3542*	13606 ± 3522*^c
AUC-Insulin	0.	5356 ± 4101	7203 ± 5044^a	5087 ± 2145
AUC-Insulin	12.	1689 ± 1652*^d	4109 ± 3213*	3039 ± 1928*

*: p <0.05 compared with before treatment in the same group; a: p <0.05 when the group-2 compared to the other two groups; b: p <0.05 when the group-3 compared to the group-1; c: p <0.05 when the group-3 compared to the other two groups; d: p <0.05 when the group-1 compared to the other two groups. (HOMA-IR: Homeostasis model assessment of insulin resistance index, AUC: Area under curve).